Table 5.
Histological disease activity at baseline and follow-up in patients with and without fibrosis progression. Fibrosis stage was determined in all biopsies.
| Parameter | No fibrosis progression (mean) | SD | Fibrosis progression (mean) | SD | p value |
|---|---|---|---|---|---|
| Baseline ∗ | |||||
| Steatosis (1–3) | 1.73 | 0.94 | 1.79 | 0.88 | 0.88 |
| Lobular inflammation (0–3) | 1.43 | 0.85 | 1.33 | 0.7 | 0.63 |
| Ballooning (0–2) | 0.97 | 0.85 | 0.88 | 0.85 | 0.69 |
| NAS (0–8) | 3.86 | 2.31 | 3.84 | 2.17 | 0.92 |
| Fibrosis (0–4) | 1.47 | 1.16 | 1.15 | 1.04 | 0.28 |
| NASH (number of patients, %) | 19/30 | 63% | 14/24 | 58% | 0.78 |
| Follow-up ∗ | |||||
| Steatosis (1–3) | 1.21 | 0.93 | 1.12 | 0.78 | 0.83 |
| Lobular inflammation (0–3) | 1.17 | 0.92 | 1.29 | 0.69 | 0.52 |
| Ballooning (0–2) | 0.54 | 0.78 | 0.94 | 0.83 | 0.11 |
| NAS (0–8) | 2.92 | 1.98 | 3.35 | 1.73 | 0.43 |
| Fibrosis (0–4) | 1.18 | 1.11 | 2.81 | 1.17 | <0.001 |
| NASH (number of patients, %) | 10/24 | 42% | 9/17 | 53% | 0.54 |
∗54 biopsies were available for scoring of NASH at baseline and 41 at follow-up. Abbreviations: NAS: NAFLD activity score; NASH: nonalcoholic steatohepatitis; SD: standard deviation.